WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte Inc., a cancer drug discovery and development company, today announced that it would report results of a Phase II clinical study of EC145 in patients with advanced lung cancer. The data will be presented as part of the 13th World Conference on Lung Cancer to be held July 31 to August 4, 2009, in San Francisco.
